Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori

doi:10.3748/wjg.122850

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 44

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 28, 2026; 32(44): 122850
Published online Nov 28, 2026. doi: 10.3748/wjg.122850

Table 1 Baseline demographic and clinical characteristics, mean ± SD/n (%)

Variable	Control (n = 66)	Trimebutine (n = 66)	P value
Age, years	47.9 ± 11.1	47.8 ± 11.2	0.932
Male sex	40 (60.6)	34 (51.5)	0.381
Body mass index, kg/m²	24.1 ± 3.0	23.8 ± 3.3	0.507
Current smoker	13 (19.7)	16 (24.2)	0.679
Habitual alcohol use	37 (56.1)	38 (57.6)	0.859
Hypertension	9 (13.6)	7 (10.6)	0.791
Diabetes mellitus	3 (4.5)	5 (7.6)	0.718
Dyslipidemia	4 (6.1)	4 (6.1)	> 0.999
Family history of gastric cancer	14 (21.2)	7 (10.6)	0.152

Comparisons used Student t-test for continuous variables and Fisher’s exact test for categorical variables.

Full Size Table

Citation: Gong EJ, Bang CS. Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori. World J Gastroenterol 2026; 32(44): 122850
URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122850.htm
DOI: https://dx.doi.org/10.3748/wjg.122850

Gong EJ, Bang CS. Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori. World J Gastroenterol 2026; 32(44): 122850 [DOI: 10.3748/wjg.122850]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.